Parkinson's Disease Pipeline Report Covering 179 Companies

Jul 31, 2016, 22:00 ET from ReportsnReports

PUNE, India, August 1, 2016 /PRNewswire/ -- adds "Parkinson's Disease - Pipeline Review, H1 2016" market research report that provides an overview of the Parkinson's Disease's therapeutic pipeline with comprehensive information on the therapeutic development complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects.

The report also reviews key players involved in the therapeutic development for Parkinson's Disease and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H1 2016 pipeline review of Parkinson's disease with 173 market data tables and 18 figures, spread across 883 pages is available at .

Companies discussed in this Parkinson's Disease Pipeline Review, H1 2016 report include AC Immune SA, Acelot, Inc., Acorda Therapeutics, Inc., Addex Therapeutics Ltd, Advinus Therapeutics Ltd, Aeolus Pharmaceuticals, Inc., AFFiRiS AG, Alexza Pharmaceuticals, Inc., Amabiotics SAS, Amarantus Bioscience Holdings, Inc., American Gene Technologies International Inc., Anavex Life Sciences Corp., Angita B.V., Antoxis Limited, APeT Holding BV, ApoPharma Inc., Aposense Ltd., Araclon Biotech, S.L., ArmaGen Inc., Arrien Pharmaceuticals, LLC, AstraZeneca Plc, Berg LLC, Bial - Portela & Ca, S.A., Bio-Modeling Systems SAS, BioArctic Neuroscience AB, Biogen, Inc., Bionature E.A. Ltd., Biopharm GmbH, Biotie Therapies Corp., BrainStorm Cell Therapeutics Inc., CalAsia Pharmaceuticals, Inc., Calico LLC, Cardax Pharmaceuticals, Inc., Carna Biosciences, Inc., Cell Cure Neurosciences, Ltd., Cellceutix Corporation, CHA Bio & Diostech Co., Ltd., Chipscreen Biosciences Ltd, Clera Inc., Clevexel Pharma SAS, Contera Pharma ApS, ContraVir Pharmaceuticals, Inc., Corium International, Inc., Corvus Pharmaceuticals, Inc., Curemark, LLC, Cynapsus Therapeutics Inc., D-Pharm Ltd., Depomed, Inc., DermaXon, LLC, Diffusion Pharmaceuticals Inc., Dizlin Medical Design AB, Domain Therapeutics SA, Edison Pharmaceuticals, Inc., Eli Lilly and Company, Ensemble Therapeutics Corporation, Euroscreen S.A., FPRT Bio Inc., Gene Solutions LLC, Genecode AS, Genentech, Inc., Genervon Biopharmaceuticals, LLC, GenKyoTex S.A., Genosco, Genzyme Corporation, H. Lundbeck A/S, Harbor Therapeutics, Inc., Heptares Therapeutics Limited, Herantis Pharma Plc, Hisamitsu Pharmaceutical Co., Inc., Huons Co., Ltd., Immune Design Corp., Immungenetics AG, Impel NeuroPharma, Inc., Intec Pharma ltd., Integrative Research Laboratories Sweden AB, InterMed Discovery GmbH, International Stem Cell Corporation, Intra-Cellular Therapies, Inc., Io Therapeutics, Inc., Iproteos S.L., Jeil Pharmaceutical Co., Ltd., Kainos Medicine, Inc., Khondrion BV, KineMed, Inc., Kyowa Hakko Kirin Co., Ltd., Lead Discovery Center GmbH, Ligand Pharmaceuticals, Inc., Living Cell Technologies Limited, Longevity Biotech, Inc, Luye Pharma Group Ltd., M et P Pharma AG, M's Science Corporation, M3 Biotechnology, Inc., MedGenesis Therapeutix Inc., Merck & Co., Inc., Merz Pharma GmbH & Co. KgaA, Metabolic Solutions Development Company, LLC, Minerva Neurosciences, Inc., Mission Therapeutics Limited, Mitochon Pharmaceuticals, Inc., MitoDys Therapeutics Limited, Motac Neuroscience Limited, Netherlands Translational Research Center B.V., Neuralstem, Inc., Neuraltus Pharmaceuticals, Inc., Neuren Pharmaceuticals Limited, NeuroDerm Ltd., Neurodyn Inc., NeuroNascent, Inc., Neuronax SAS, NeurOp, Inc, NeuroPhage Pharmaceuticals, Inc., Neuropore Therapies, Inc., New World Laboratories, Inc., Newron Pharmaceuticals S.p.A., nLife Therapeutics, S.L., NLS Pharma Group, Novartis AG, NsGene A/S, Omeros Corporation, Oncodesign SA, Ono Pharmaceutical Co., Ltd., OPKO Health, Inc., Orion Oyj, Oryzon Genomics S.A., Osmotica Pharmaceutical Corp., Oxford BioMedica Plc, Peptron, Inc., Pfizer Inc., Pharma Two B Ltd, PharmatrophiX, Inc., Pharmaxis Limited, Pharmicell Co., Ltd., Pharnext SAS, Prana Biotechnology Limited, Prexton Therapeutics SA, Primary Peptides, Inc., Promentis Pharmaceuticals, Inc., Promius Pharma, LLC, Proteostasis Therapeutics, Inc., Prothena Corporation Plc, QR Pharma, Inc., Raptor Pharmaceutical Corp., Reliance Life Sciences Pvt. Ltd., reMYND NV, Retrotope, Inc, RhinoCyte, Inc., Saje Pharma, LLC, SanBio, Inc., Saneron CCEL Therapeutics, Inc., Saniona AB, Sellas Inc., Serina Therapeutics, Inc., Shire Plc, Sigma-Tau S.p.A., SignPath Pharma Inc, Signum Biosciences, Inc., SK Biopharmaceuticals Co., Ltd., STATegics, Inc., Stelic Institute & Co., Inc., Synovo GmbH, Synthonics, Inc., Takara Bio Inc., Takeda Pharmaceutical Company Limited, TauRx Therapeutics Ltd., TechnoPhage SA, Teikoku Pharma USA, Inc., Teva Pharmaceutical Industries Ltd., Titan Pharmaceuticals, Inc., Trevena, Inc., TyrNovo Ltd., UCB S.A., UniQure N.V., Vanton Research Laboratory, LLC, Varinel, Inc., VistaGen Therapeutics , Inc., VivaCell Biotechnology Espana S.L., Voyager Therapeutics, Inc. and Wellstat Therapeutics Corporation.

Order a copy of Parkinson's Disease - Pipeline Review, H1 2016 market research report @ .

Explore more reports on Pharmaceuticals.

About Us: is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1 888 391 5441

Connect With Us on:
G+ / Google Plus:

SOURCE ReportsnReports